Clinical oncology最新文献

英文中文

Customized Non-invasive Brachytherapy With Tailored Surface Moulds: An Experience From a Tertiary Care Centre. 定制无创近距离治疗与定制表面模具：来自三级护理中心的经验。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-07 DOI: 10.1016/j.clon.2026.104033

N Lall, S Choudhary, L M Aggarwal, A Mourya, G Priean V, S Sachin, G Bui, D Nandi, A K Jaiswal, R Ranjan

Aim: Surface mould brachytherapy (SMBT) is an effective non-invasive treatment option for patients with skin cancer and other superficial tumours. We describe the detailed technique of uniquely treated patients of various histology using customized tailor-made surface moulds and evaluated clinical outcomes, toxicity profile, and quality of life of patients treated with SMBT.

Materials and methods: In this retrospective study, we have evaluated nine patients treated with surface moulds using iridium-192-based high-dose-rate brachytherapy.

Results: The median age was 34 years. The histopathological diagnosis included squamous cell carcinoma (n=4), followed by giant cell tumour (n=2), and 1 each of angiosarcoma, dermatofibrosarcoma protuberans, and clear cell sarcoma. The most common radiotherapy dose schedule was 60-66 Gray at 2 Gray per fraction. After a median follow-up of 24 months, local control was 100%. At the end of five years, overall survival (OS) and disease-free survival (DFS) were 88.89%. The maximum acute skin and subcutaneous toxicity grade II was observed in 5 (55.6%) patients and grade III in 4 (44.4%) patients, maximum late toxicity was grade III in 3 (33.3%) patients. Poorer Dermatology Life Quality Index scores were statistically significantly associated with higher overdose index (>0) (P=.039), and V_150% >40% (P=.039).

Conclusion: SMBT is an effective modality to achieve excellent local control in patients of skin and superficial tumours. After five years, OS and DFS both were 88.89%. It was well tolerated with manageable grade II,III acute and late skin toxicities.

目的：表面霉菌近距离放射治疗（SMBT）是一种有效的非侵入性治疗皮肤癌和其他浅表肿瘤的选择。我们描述了使用定制的定制表面模具对不同组织学患者进行独特治疗的详细技术，并评估了SMBT治疗患者的临床结果、毒性特征和生活质量。材料和方法：在这项回顾性研究中，我们评估了9例使用基于铱-192的高剂量近距离放射治疗表面模具的患者。结果：中位年龄34岁。组织病理学诊断为鳞状细胞癌（n=4），其次是巨细胞瘤（n=2），血管肉瘤、隆突性皮肤纤维肉瘤和透明细胞肉瘤各1例。最常见的放疗剂量计划是60-66格雷，每分数2格雷。中位随访24个月后，局部控制率为100%。5年后，总生存期（OS）和无病生存期（DFS）为88.89%。急性皮肤和皮下毒性最大为II级5例（55.6%），III级4例（44.4%），晚期毒性最大为III级3例（33.3%）。较差的Dermatology Life Quality Index评分与较高的用药过量指数（>）（P= 0.039）和V150% >40% （P= 0.039）有统计学意义。结论：SMBT是一种有效的局部控制皮肤及浅表肿瘤的方法。5年后，OS和DFS均为88.89%。耐受性良好，II级、III级急性和晚期皮肤毒性可控。

{"title":"Customized Non-invasive Brachytherapy With Tailored Surface Moulds: An Experience From a Tertiary Care Centre.","authors":"N Lall, S Choudhary, L M Aggarwal, A Mourya, G Priean V, S Sachin, G Bui, D Nandi, A K Jaiswal, R Ranjan","doi":"10.1016/j.clon.2026.104033","DOIUrl":"https://doi.org/10.1016/j.clon.2026.104033","url":null,"abstract":"<p><strong>Aim: </strong>Surface mould brachytherapy (SMBT) is an effective non-invasive treatment option for patients with skin cancer and other superficial tumours. We describe the detailed technique of uniquely treated patients of various histology using customized tailor-made surface moulds and evaluated clinical outcomes, toxicity profile, and quality of life of patients treated with SMBT.</p><p><strong>Materials and methods: </strong>In this retrospective study, we have evaluated nine patients treated with surface moulds using iridium-192-based high-dose-rate brachytherapy.</p><p><strong>Results: </strong>The median age was 34 years. The histopathological diagnosis included squamous cell carcinoma (n=4), followed by giant cell tumour (n=2), and 1 each of angiosarcoma, dermatofibrosarcoma protuberans, and clear cell sarcoma. The most common radiotherapy dose schedule was 60-66 Gray at 2 Gray per fraction. After a median follow-up of 24 months, local control was 100%. At the end of five years, overall survival (OS) and disease-free survival (DFS) were 88.89%. The maximum acute skin and subcutaneous toxicity grade II was observed in 5 (55.6%) patients and grade III in 4 (44.4%) patients, maximum late toxicity was grade III in 3 (33.3%) patients. Poorer Dermatology Life Quality Index scores were statistically significantly associated with higher overdose index (>0) (P=.039), and V<sub>150%</sub> >40% (P=.039).</p><p><strong>Conclusion: </strong>SMBT is an effective modality to achieve excellent local control in patients of skin and superficial tumours. After five years, OS and DFS both were 88.89%. It was well tolerated with manageable grade II,III acute and late skin toxicities.</p>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"104033"},"PeriodicalIF":3.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

‘Letter to Editor: Impact of Treatment Decisions on Survival Outcomes in Elderly Patients With Non–small Cell Lung Cancer: A Retrospective Real-World Study’ 致编辑：治疗决定对老年非小细胞肺癌患者生存结果的影响：一项回顾性现实世界研究

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-07 DOI: 10.1016/j.clon.2026.104030

A. Irfan

引用次数: 0

Authors’ Response to Re-evaluating the 30 Gy Dose for Chest Wall-Abutting Tumours in Single-Fraction Stereotactic Ablative Radiotherapy: Evidence From a Population-Based Study 作者对在单次立体定向消融放疗中重新评估30 Gy胸壁邻近肿瘤剂量的反应：来自人群研究的证据。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-07 DOI: 10.1016/j.clon.2026.104031

J.M. Callueng , M. Liu , B. Mou

引用次数: 0

OncoFlash: Research Updates in a Flash! (Feb 2026 Edition) OncoFlash：研究更新在一个闪光！（2026年2月版）

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-06 DOI: 10.1016/j.clon.2026.104034

D.J. Hughes , R. Simoes

引用次数: 0

Stereotactic Body Radiotherapy for Extracranial Oligometastatic Pancreatobiliary Cancer 立体定向放射治疗颅外少转移性胰胆癌。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-01 DOI: 10.1016/j.clon.2025.103995

A.N. Mian , S. Myrehaug , S. Ng , A. Taggar , Y. Ung , S. Ali , P. Cheung , A.V. Louie , I. Poon , L. Zhang , H.T. Chung

Aims

In an oligometastatic disease, stereotactic body radiotherapy (SBRT) is being increasingly used in many different histologies to delay progression. However, by virtue of pancreatobiliary cancers not being as common and more aggressive natural history, data on its usage in pancreatobiliary cancers have been limited. Herein, our study aims to evaluate the outcomes of extracranial SBRT for oligometastatic pancreatobiliary cancers.

Materials and methods

A retrospective review was conducted on patients with oligometastatic pancreatobiliary cancer treated with extracranial SBRT between 2014 and 2023 at our institution. The analysis examined cumulative incidence of local failure (LF), progression-free survival (PFS), cumulative incidence of starting or changing systemic therapy (SCST), overall survival (OS) and Radiation Therapy Oncology Group—graded treatment-related toxicities. Kaplan–Meier methodology and Cox proportional hazard models were used for survival analysis.

Results

Among the 62 patients (115 lesions) identified, the median follow-up was 13.4 months. By primary location, 71% had pancreatic cancer, 15% had cholangiocarcinoma, and 15% had ampullary cancer. Synchronous and metachronous oligometastatic disease was 37% and 63%, respectively. Eighty-seven percent of patients had 1-2 lesions treated with SBRT. At 12 months, LF, PFS, SCST, and OS was 21.5%, 28.0%, 33.6% and 61.7%, respectively. On multivariable analysis, the only predictor of worse PFS was higher PTV volume. No grade 3-5 toxicities were reported.

Conclusion

Similar to other cancers, SBRT appears to be a promising option for those with oligometastatic pancreatobiliary cancer. More research in how to optimise integration of SBRT in a multidisciplinary setting for this challenging disease would be of benefit.

目的：在低转移性疾病中，立体定向体放疗（SBRT）越来越多地用于许多不同的组织学以延缓进展。然而，由于胰胆管癌不常见且具有侵袭性的自然病史，其在胰胆管癌中的应用数据有限。在此，我们的研究旨在评估颅外SBRT治疗低转移性胰胆癌的结果。材料与方法：回顾性分析我院2014 - 2023年经颅外SBRT治疗的少转移性胰胆癌患者。该分析检查了局部失败（LF）的累积发生率、无进展生存期（PFS）、开始或改变全身治疗（SCST）的累积发生率、总生存期（OS）和放射治疗肿瘤组分级治疗相关毒性。生存率分析采用Kaplan-Meier方法和Cox比例风险模型。结果：确诊的62例患者（115个病变）中位随访时间为13.4个月。按原发部位划分，71%为胰腺癌，15%为胆管癌，15%为壶腹癌。同步性和异时性少转移性疾病分别为37%和63%。87%的患者有1-2个病变接受了SBRT治疗。12个月时，LF、PFS、SCST和OS分别为21.5%、28.0%、33.6%和61.7%。在多变量分析中，PTV体积增大是PFS恶化的唯一预测因子。3-5级毒性未见报道。结论：与其他癌症类似，SBRT似乎是低转移性胰胆癌患者的一个有希望的选择。更多关于如何在多学科背景下优化SBRT整合治疗这一具有挑战性的疾病的研究将是有益的。

{"title":"Stereotactic Body Radiotherapy for Extracranial Oligometastatic Pancreatobiliary Cancer","authors":"A.N. Mian , S. Myrehaug , S. Ng , A. Taggar , Y. Ung , S. Ali , P. Cheung , A.V. Louie , I. Poon , L. Zhang , H.T. Chung","doi":"10.1016/j.clon.2025.103995","DOIUrl":"10.1016/j.clon.2025.103995","url":null,"abstract":"<div><h3><em>Aims</em></h3><div>In an oligometastatic disease, stereotactic body radiotherapy (SBRT) is being increasingly used in many different histologies to delay progression. However, by virtue of pancreatobiliary cancers not being as common and more aggressive natural history, data on its usage in pancreatobiliary cancers have been limited. Herein, our study aims to evaluate the outcomes of extracranial SBRT for oligometastatic pancreatobiliary cancers.</div></div><div><h3><em>Materials and methods</em></h3><div>A retrospective review was conducted on patients with oligometastatic pancreatobiliary cancer treated with extracranial SBRT between 2014 and 2023 at our institution. The analysis examined cumulative incidence of local failure (LF), progression-free survival (PFS), cumulative incidence of starting or changing systemic therapy (SCST), overall survival (OS) and Radiation Therapy Oncology Group—graded treatment-related toxicities. Kaplan–Meier methodology and Cox proportional hazard models were used for survival analysis.</div></div><div><h3><em>Results</em></h3><div>Among the 62 patients (115 lesions) identified, the median follow-up was 13.4 months. By primary location, 71% had pancreatic cancer, 15% had cholangiocarcinoma, and 15% had ampullary cancer. Synchronous and metachronous oligometastatic disease was 37% and 63%, respectively. Eighty-seven percent of patients had 1-2 lesions treated with SBRT. At 12 months, LF, PFS, SCST, and OS was 21.5%, 28.0%, 33.6% and 61.7%, respectively. On multivariable analysis, the only predictor of worse PFS was higher PTV volume. No grade 3-5 toxicities were reported.</div></div><div><h3><em>Conclusion</em></h3><div>Similar to other cancers, SBRT appears to be a promising option for those with oligometastatic pancreatobiliary cancer. More research in how to optimise integration of SBRT in a multidisciplinary setting for this challenging disease would be of benefit.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103995"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Authors' Response to the Letter Titled: Enhancing Treatment Resilience in Palliative Oesophago-Gastric Cancer: Nutritional, Access, and Scoring Considerations 作者对题为“增强姑息性食道-胃癌的治疗弹性：营养、获取和评分考虑”的信件的回应。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-01 DOI: 10.1016/j.clon.2025.103998

K. Datta , A. Byrne , D. Holland-Hart

引用次数: 0

RCR Meetings 软的会议

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-01 DOI: 10.1016/S0936-6555(26)00012-9

引用次数: 0

Paid MBP advert BGOC 2026-210x280_01 付费MBP广告BGOC 2026-210x280_01

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-01 DOI: 10.1016/S0936-6555(26)00018-X

引用次数: 0

Defining the Clinical Target Volume in Postoperative Thymic Epithelial Tumours - A Clinical Practice Guide for UK Clinical Oncologists 确定术后胸腺上皮肿瘤的临床靶体积-英国临床肿瘤学家的临床实践指南。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-01 DOI: 10.1016/j.clon.2025.103996

S.D. Robinson , P. Bhatnagar , R. Duerden , S. Dubash , J. Glackin , E. Josephides , D. Lynskey , N. Panakis , C. Peedell , D. Smith , S. Datta , R. Kandadai , A. Kirk , P. Bishop , S. Yancheva , S. Harden , P. Shaw , A. Cascales , D. Abdulwahid , A.M. Shiarli , Y. Summers

Background

Thymic epithelial tumours (TETs) are rare tumours, and most patients undergo curative resection. A minority require post-operative radiotherapy (PORT); however, current published guidelines provide differing recommendations. With few cases, a new staging system, increasing use of minimally invasive operative techniques, and challenging histopathology, postoperative radiotherapy planning is increasingly difficult with significant national variation. To bridge this gap, the multidisciplinary British Thoracic Oncology Group (BTOG) Thymic Malignancies Special Interest Group convened a working group to produce a user-friendly, practical guideline for TET postoperative radiotherapy.

Methods

Through synthesis of current published guidelines, expert multidisciplinary opinions (radiologists, surgeons, histopathologists, and clinical oncologists), and a blinded clinical target volume (CTV) contouring assessment, areas of agreement and best practice were identified.

Results

Subsequently, mandatory, and optional, recommendations were agreed for all steps of the postoperative radiotherapy planning process, including which areas to treat, radiotherapy planning techniques, and radiotherapy dose fractionation.

Conclusion

Implementation of this national guideline will improve clinician knowledge related to postoperative radiotherapy for TETs and should reduce unwarranted variations in practice.

背景：胸腺上皮肿瘤（TETs）是一种罕见的肿瘤，大多数患者接受根治性切除。少数需要术后放疗（PORT）；然而，目前出版的指南提供了不同的建议。由于病例少，新的分期系统，微创手术技术的使用越来越多，以及组织病理学的挑战，术后放疗计划越来越困难，且各国差异显著。为了弥补这一差距，多学科的英国胸腺肿瘤小组（BTOG）胸腺恶性肿瘤特别兴趣小组召集了一个工作组，制定了一个用户友好的、实用的TET术后放疗指南。方法：通过综合当前出版的指南，多学科专家意见（放射科医生、外科医生、组织病理学家和临床肿瘤学家），以及盲法临床靶体积（CTV）轮廓评估，确定了一致的领域和最佳实践。结果：随后，对术后放疗计划过程的所有步骤，包括治疗区域、放疗计划技术和放疗剂量分割，强制性和可选性的建议达成一致。结论：本国家指南的实施将提高临床医生对TETs术后放疗的相关知识，并应减少实践中不必要的变化。

{"title":"Defining the Clinical Target Volume in Postoperative Thymic Epithelial Tumours - A Clinical Practice Guide for UK Clinical Oncologists","authors":"S.D. Robinson , P. Bhatnagar , R. Duerden , S. Dubash , J. Glackin , E. Josephides , D. Lynskey , N. Panakis , C. Peedell , D. Smith , S. Datta , R. Kandadai , A. Kirk , P. Bishop , S. Yancheva , S. Harden , P. Shaw , A. Cascales , D. Abdulwahid , A.M. Shiarli , Y. Summers","doi":"10.1016/j.clon.2025.103996","DOIUrl":"10.1016/j.clon.2025.103996","url":null,"abstract":"<div><h3>Background</h3><div>Thymic epithelial tumours (TETs) are rare tumours, and most patients undergo curative resection. A minority require post-operative radiotherapy (PORT); however, current published guidelines provide differing recommendations. With few cases, a new staging system, increasing use of minimally invasive operative techniques, and challenging histopathology, postoperative radiotherapy planning is increasingly difficult with significant national variation. To bridge this gap, the multidisciplinary British Thoracic Oncology Group (BTOG) Thymic Malignancies Special Interest Group convened a working group to produce a user-friendly, practical guideline for TET postoperative radiotherapy.</div></div><div><h3>Methods</h3><div>Through synthesis of current published guidelines, expert multidisciplinary opinions (radiologists, surgeons, histopathologists, and clinical oncologists), and a blinded clinical target volume (CTV) contouring assessment, areas of agreement and best practice were identified.</div></div><div><h3>Results</h3><div>Subsequently, mandatory, and optional, recommendations were agreed for all steps of the postoperative radiotherapy planning process, including which areas to treat, radiotherapy planning techniques, and radiotherapy dose fractionation.</div></div><div><h3>Conclusion</h3><div>Implementation of this national guideline will improve clinician knowledge related to postoperative radiotherapy for TETs and should reduce unwarranted variations in practice.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103996"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches 结肠直肠癌肝转移消失的导航：手术和非手术方法综述。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-01-01 DOI: 10.1016/j.clon.2025.103981

I. Valle , C. Conticello , D. Ravizza , D. Lavacchi , D. Pallaoro , G.L. Grazi , D. Rossini , L. Antonuzzo

Colorectal liver metastases pose a significant clinical challenge for the multidisciplinary team (MDT), with the phenomenon of disappearing liver metastases (DLMs) following chemotherapy adding further complexity. DLMs, defined as the radiological disappearance of liver metastases after systemic therapy, require careful evaluation as the pathological complete response is not always guaranteed. To comprehensively address and analyse the key aspects of this complex issue, we performed a literature search using PubMed and Embase, focussing on studies reporting outcomes of different treatment approaches, imaging techniques, and prognostic factors.

The current evidence emphasises the pivotal role of advanced imaging modalities-such as gadolinium ethoxybenzyl dimeglumine-enhanced magnetic resonance imaging (MRI) and contrast-enhanced intraoperative ultrasound-in accurately assessing high-risk patients with DLMs (eg, lesions <2 cm, synchronous metastases or those treated with oxaliplatin-based chemotherapy). Using these techniques both preoperatively and intraoperatively is crucial for precise localisation of DLMs. The literature also highlights the importance of an MDT approach to optimise patient management, ensuring treatment decisions are tailored to individual patient and tumour characteristics. A ‘watch-and-wait’ strategy may be appropriate for selected patients with favourable prognostic factors, whereas locoregional treatments are preferable for fit patients with adequate residual liver volume or DLMs adjacent to visible residual disease. To support clinical decision-making, our group has developed a simplified algorithm to guide clinicians.

结直肠肝转移对多学科团队（MDT）来说是一个重大的临床挑战，化疗后肝转移（DLMs）消失的现象进一步增加了复杂性。DLMs被定义为全身治疗后肝转移的放射学消失，需要仔细评估，因为病理完全缓解并不总是得到保证。为了全面解决和分析这一复杂问题的关键方面，我们使用PubMed和Embase进行了文献检索，重点关注不同治疗方法、成像技术和预后因素的研究结果。目前的证据强调了先进的成像方式的关键作用，如钆乙氧基苄基二聚氰胺增强磁共振成像（MRI）和造影剂增强术中超声在准确评估DLMs高危患者（如病变）中的作用

{"title":"Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches","authors":"I. Valle , C. Conticello , D. Ravizza , D. Lavacchi , D. Pallaoro , G.L. Grazi , D. Rossini , L. Antonuzzo","doi":"10.1016/j.clon.2025.103981","DOIUrl":"10.1016/j.clon.2025.103981","url":null,"abstract":"<div><div>Colorectal liver metastases pose a significant clinical challenge for the multidisciplinary team (MDT), with the phenomenon of disappearing liver metastases (DLMs) following chemotherapy adding further complexity. DLMs, defined as the radiological disappearance of liver metastases after systemic therapy, require careful evaluation as the pathological complete response is not always guaranteed. To comprehensively address and analyse the key aspects of this complex issue, we performed a literature search using PubMed and Embase, focussing on studies reporting outcomes of different treatment approaches, imaging techniques, and prognostic factors.</div><div>The current evidence emphasises the pivotal role of advanced imaging modalities-such as gadolinium ethoxybenzyl dimeglumine-enhanced magnetic resonance imaging (MRI) and contrast-enhanced intraoperative ultrasound-in accurately assessing high-risk patients with DLMs (eg, lesions <2 cm, synchronous metastases or those treated with oxaliplatin-based chemotherapy). Using these techniques both preoperatively and intraoperatively is crucial for precise localisation of DLMs. The literature also highlights the importance of an MDT approach to optimise patient management, ensuring treatment decisions are tailored to individual patient and tumour characteristics. A ‘watch-and-wait’ strategy may be appropriate for selected patients with favourable prognostic factors, whereas locoregional treatments are preferable for fit patients with adequate residual liver volume or DLMs adjacent to visible residual disease. To support clinical decision-making, our group has developed a simplified algorithm to guide clinicians.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103981"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀